P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis

Paola Fabbrizio, Savina Apolloni, Andrea Bianchi, Illari Salvatori, Cristiana Valle, Chiara Lanzuolo, Caterina Bendotti, Giovanni Nardo, Cinzia Volonté

Research output: Contribution to journalArticle

Abstract

Muscle weakness plays an important role in neuromuscular disorders comprising amyotrophic lateral sclerosis (ALS). However, it is not established whether muscle denervation originates from the motor neurons, the muscles or more likely both. Previous studies have shown that the expression of the SOD1G93A mutation in skeletal muscles causes denervation of the neuromuscular junctions, inability to regenerate and consequent atrophy, all clear symptoms of ALS. In this work, we used SOD1G93A mice, a model that best mimics some pathological features of both familial and sporadic ALS, and we investigated some biological effects induced by the activation of the P2X7 receptor in the skeletal muscles. The P2X7, belonging to the ionotropic family of purinergic receptors for extracellular ATP, is abundantly expressed in the healthy skeletal muscles, where it controls cell duplication, differentiation, regeneration or death. In particular, we evaluated whether an in vivo treatment in SOD1G93A mice with the P2X7 specific agonist 2′(3′)-O-(4-Benzoylbenzoyl) adenosine5′-triphosphate (BzATP) just before the onset of a pathological neuromuscular phenotype could exert beneficial effects in the skeletal muscles. Our findings indicate that stimulation of P2X7 improves the innervation and metabolism of myofibers, moreover elicits the proliferation/differentiation of satellite cells, thus preventing the denervation atrophy of skeletal muscles in SOD1G93A mice. Overall, this study suggests that a P2X7-targeted and site-specific modulation might be a strategy to interfere with the complex multifactorial and multisystem nature of ALS.

Original languageEnglish
JournalBrain Pathology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Amyotrophic Lateral Sclerosis
Regeneration
Skeletal Muscle
Muscle Denervation
Atrophy
Cell Differentiation
Purinergic P2X7 Receptors
Naphazoline
Purinergic Receptors
Neuromuscular Junction
Muscle Weakness
Motor Neurons
Denervation
Adenosine Triphosphate
Phenotype
Muscles
Mutation
Amyotrophic lateral sclerosis 1

Keywords

  • amyotrophic lateral sclerosis
  • purinergic receptors
  • skeletal muscle
  • SOD1G93A mice

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. / Fabbrizio, Paola; Apolloni, Savina; Bianchi, Andrea; Salvatori, Illari; Valle, Cristiana; Lanzuolo, Chiara; Bendotti, Caterina; Nardo, Giovanni; Volonté, Cinzia.

In: Brain Pathology, 01.01.2019.

Research output: Contribution to journalArticle

@article{5cfb7e986f6c4581ae08191715f4e4b3,
title = "P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis",
abstract = "Muscle weakness plays an important role in neuromuscular disorders comprising amyotrophic lateral sclerosis (ALS). However, it is not established whether muscle denervation originates from the motor neurons, the muscles or more likely both. Previous studies have shown that the expression of the SOD1G93A mutation in skeletal muscles causes denervation of the neuromuscular junctions, inability to regenerate and consequent atrophy, all clear symptoms of ALS. In this work, we used SOD1G93A mice, a model that best mimics some pathological features of both familial and sporadic ALS, and we investigated some biological effects induced by the activation of the P2X7 receptor in the skeletal muscles. The P2X7, belonging to the ionotropic family of purinergic receptors for extracellular ATP, is abundantly expressed in the healthy skeletal muscles, where it controls cell duplication, differentiation, regeneration or death. In particular, we evaluated whether an in vivo treatment in SOD1G93A mice with the P2X7 specific agonist 2′(3′)-O-(4-Benzoylbenzoyl) adenosine5′-triphosphate (BzATP) just before the onset of a pathological neuromuscular phenotype could exert beneficial effects in the skeletal muscles. Our findings indicate that stimulation of P2X7 improves the innervation and metabolism of myofibers, moreover elicits the proliferation/differentiation of satellite cells, thus preventing the denervation atrophy of skeletal muscles in SOD1G93A mice. Overall, this study suggests that a P2X7-targeted and site-specific modulation might be a strategy to interfere with the complex multifactorial and multisystem nature of ALS.",
keywords = "amyotrophic lateral sclerosis, purinergic receptors, skeletal muscle, SOD1G93A mice",
author = "Paola Fabbrizio and Savina Apolloni and Andrea Bianchi and Illari Salvatori and Cristiana Valle and Chiara Lanzuolo and Caterina Bendotti and Giovanni Nardo and Cinzia Volont{\'e}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bpa.12774",
language = "English",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis

AU - Fabbrizio, Paola

AU - Apolloni, Savina

AU - Bianchi, Andrea

AU - Salvatori, Illari

AU - Valle, Cristiana

AU - Lanzuolo, Chiara

AU - Bendotti, Caterina

AU - Nardo, Giovanni

AU - Volonté, Cinzia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Muscle weakness plays an important role in neuromuscular disorders comprising amyotrophic lateral sclerosis (ALS). However, it is not established whether muscle denervation originates from the motor neurons, the muscles or more likely both. Previous studies have shown that the expression of the SOD1G93A mutation in skeletal muscles causes denervation of the neuromuscular junctions, inability to regenerate and consequent atrophy, all clear symptoms of ALS. In this work, we used SOD1G93A mice, a model that best mimics some pathological features of both familial and sporadic ALS, and we investigated some biological effects induced by the activation of the P2X7 receptor in the skeletal muscles. The P2X7, belonging to the ionotropic family of purinergic receptors for extracellular ATP, is abundantly expressed in the healthy skeletal muscles, where it controls cell duplication, differentiation, regeneration or death. In particular, we evaluated whether an in vivo treatment in SOD1G93A mice with the P2X7 specific agonist 2′(3′)-O-(4-Benzoylbenzoyl) adenosine5′-triphosphate (BzATP) just before the onset of a pathological neuromuscular phenotype could exert beneficial effects in the skeletal muscles. Our findings indicate that stimulation of P2X7 improves the innervation and metabolism of myofibers, moreover elicits the proliferation/differentiation of satellite cells, thus preventing the denervation atrophy of skeletal muscles in SOD1G93A mice. Overall, this study suggests that a P2X7-targeted and site-specific modulation might be a strategy to interfere with the complex multifactorial and multisystem nature of ALS.

AB - Muscle weakness plays an important role in neuromuscular disorders comprising amyotrophic lateral sclerosis (ALS). However, it is not established whether muscle denervation originates from the motor neurons, the muscles or more likely both. Previous studies have shown that the expression of the SOD1G93A mutation in skeletal muscles causes denervation of the neuromuscular junctions, inability to regenerate and consequent atrophy, all clear symptoms of ALS. In this work, we used SOD1G93A mice, a model that best mimics some pathological features of both familial and sporadic ALS, and we investigated some biological effects induced by the activation of the P2X7 receptor in the skeletal muscles. The P2X7, belonging to the ionotropic family of purinergic receptors for extracellular ATP, is abundantly expressed in the healthy skeletal muscles, where it controls cell duplication, differentiation, regeneration or death. In particular, we evaluated whether an in vivo treatment in SOD1G93A mice with the P2X7 specific agonist 2′(3′)-O-(4-Benzoylbenzoyl) adenosine5′-triphosphate (BzATP) just before the onset of a pathological neuromuscular phenotype could exert beneficial effects in the skeletal muscles. Our findings indicate that stimulation of P2X7 improves the innervation and metabolism of myofibers, moreover elicits the proliferation/differentiation of satellite cells, thus preventing the denervation atrophy of skeletal muscles in SOD1G93A mice. Overall, this study suggests that a P2X7-targeted and site-specific modulation might be a strategy to interfere with the complex multifactorial and multisystem nature of ALS.

KW - amyotrophic lateral sclerosis

KW - purinergic receptors

KW - skeletal muscle

KW - SOD1G93A mice

UR - http://www.scopus.com/inward/record.url?scp=85070816643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070816643&partnerID=8YFLogxK

U2 - 10.1111/bpa.12774

DO - 10.1111/bpa.12774

M3 - Article

AN - SCOPUS:85070816643

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

ER -